Literature DB >> 12544413

Metabolic complications of antiretroviral therapy in children.

Ethan G Leonard1, Grace A McComsey.   

Abstract

Survival in HIV-infected children has greatly improved with the introduction of highly active antiretroviral therapy. Children are more vulnerable than adults to metabolic side effects of therapy because of its potential impact on growth and the children's likely greater cumulative exposure. This review summarizes the epidemiology and management of lipodystrophy, dyslipidemia, insulin resistance, hyperlactatemia, osteopenia and growth failure in HIV-infected children.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12544413     DOI： 10.1097/00006454-200301000-00018

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  22 in total

1.  Longevity on Antiretroviral Therapy for Children Living with HIV/AIDS--A Price to Pay for Success?

Authors:  Mamatha M Lala; Rashid H Merchant
Journal:  Indian J Pediatr       Date:  2016-02-06       Impact factor: 1.967

2.  Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

Authors:  Ana María Sánchez Torres; Raquel Munoz Muniz; Rosario Madero; Clementina Borque; María Jesús García-Miguel; María Isabel De José Gómez
Journal:  Eur J Pediatr       Date:  2005-01-14       Impact factor: 3.183

Review 3.  Management of antiretroviral therapy in neonates, children, and adolescents.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

Review 4.  Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done?

Authors:  Emanuele Pontali
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.

Authors:  Agnes Langat; Sarah Benki-Nugent; Dalton Wamalwa; Ken Tapia; Evelyn Ngugi; Lara Diener; Barbra A Richardson; Ann Melvin; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

7.  Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Authors:  Grace M Aldrovandi; Jane C Lindsey; Denise L Jacobson; Amanda Zadzilka; Elizabeth Sheeran; Jack Moye; Peggy Borum; William A Meyer; Dana S Hardin; Kathleen Mulligan
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

8.  Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.

Authors:  Anirban Mandal; Aparna Mukherjee; R Lakshmy; Sushil K Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2015-09-03       Impact factor: 1.967

9.  Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.

Authors:  Gloria Huerta-García; José G Vazquez-Rosales; José A Mata-Marín; Leoncio Peregrino-Bejarano; Eric Flores-Ruiz; Fortino Solórzano-Santos
Journal:  Pediatr Res       Date:  2016-03-21       Impact factor: 3.756

Review 10.  Current and future antiretroviral treatment options in paediatric HIV infection.

Authors:  Carlo Giaquinto; Erika Morelli; Federica Fregonese; Osvalda Rampon; Martina Penazzato; Anita de Rossi; Ruggero D'Elia
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.